FI3658194T3 - Dual mode -radiomerkkiaine ja -terapia - Google Patents

Dual mode -radiomerkkiaine ja -terapia Download PDF

Info

Publication number
FI3658194T3
FI3658194T3 FIEP18743540.9T FI18743540T FI3658194T3 FI 3658194 T3 FI3658194 T3 FI 3658194T3 FI 18743540 T FI18743540 T FI 18743540T FI 3658194 T3 FI3658194 T3 FI 3658194T3
Authority
FI
Finland
Prior art keywords
radioactive
compound
cation
optionally
chelated
Prior art date
Application number
FIEP18743540.9T
Other languages
English (en)
Finnish (fi)
Inventor
Alexander Josef Wurzer
Hans-Jürgen Wester
Matthias Johannes Eiber
Original Assignee
Univ Muenchen Tech
Technische Univ Muenchen Klinikum Rechts Der Isar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech, Technische Univ Muenchen Klinikum Rechts Der Isar filed Critical Univ Muenchen Tech
Application granted granted Critical
Publication of FI3658194T3 publication Critical patent/FI3658194T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0402Organic compounds carboxylic acid carriers, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nuclear Medicine (AREA)
FIEP18743540.9T 2017-07-28 2018-07-30 Dual mode -radiomerkkiaine ja -terapia FI3658194T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17183795 2017-07-28
PCT/EP2018/070533 WO2019020831A1 (en) 2017-07-28 2018-07-30 AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES

Publications (1)

Publication Number Publication Date
FI3658194T3 true FI3658194T3 (fi) 2025-02-28

Family

ID=59501286

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18743540.9T FI3658194T3 (fi) 2017-07-28 2018-07-30 Dual mode -radiomerkkiaine ja -terapia

Country Status (20)

Country Link
US (3) US11413360B2 (enExample)
EP (3) EP4000640A1 (enExample)
JP (2) JP7059372B2 (enExample)
KR (2) KR102752620B1 (enExample)
CN (1) CN111132700B (enExample)
AU (2) AU2018308699B2 (enExample)
BR (1) BR112020001785A2 (enExample)
CA (1) CA3071315A1 (enExample)
DK (1) DK3658194T3 (enExample)
EA (1) EA202090370A1 (enExample)
ES (1) ES3011272T3 (enExample)
FI (1) FI3658194T3 (enExample)
HU (1) HUE070098T2 (enExample)
IL (2) IL272291B2 (enExample)
MX (2) MX2020000352A (enExample)
PL (1) PL3658194T3 (enExample)
PT (1) PT3658194T (enExample)
SG (1) SG11202000725WA (enExample)
WO (1) WO2019020831A1 (enExample)
ZA (1) ZA202000467B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3658194T3 (pl) 2017-07-28 2025-09-15 Technische Universität München Radioznacznik i środki radioterapeutyczne o podwójnym trybie działania
KR20210153036A (ko) * 2019-01-30 2021-12-16 테크니쉐 우니베르지테트 뮌헨 암 진단 영상화제들
JP7421232B2 (ja) * 2019-01-30 2024-01-24 テクニシェ ユニバーシタット ミュンヘン フッ化ケイ素アクセプタ置換放射性医薬品とその前駆体
FI3917626T3 (fi) 2019-01-30 2023-08-17 Univ Muenchen Tech Psma:ta sitova kaksimuotoinen radiomerkkiaine ja terapeuttinen aine
CN112168978B (zh) * 2019-07-03 2022-01-11 北京大学 一种抗体偶联药物及其药物组合物与应用
CA3155519A1 (en) * 2019-10-29 2021-05-06 Steve Shih-Lin Huang Psma-targeting imaging agents
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
GB202005282D0 (en) * 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
WO2022018264A1 (en) 2020-07-23 2022-01-27 Technische Universität München Silicon-containing ligand compounds
CA3191472A1 (en) 2020-09-03 2022-03-10 Curium Us Llc Radiolabeling and formulation for scale up of 64cu-dotatate
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
AU2022219543A1 (en) 2021-02-15 2023-08-17 Technische Universität München Dual mode radiotracer and therapeutics
AU2022273184A1 (en) * 2021-05-14 2023-10-12 Technische Universität München Radiopharmaceutical somatostatin receptor ligands and precursors thereof
GB202108779D0 (en) 2021-06-18 2021-08-04 Blue Earth Diagnostics Ltd Si-at therapeutic/diagnostic compounds
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
AU2022323741A1 (en) * 2021-08-05 2024-02-01 Technische Universität München Ligand compounds comprising a chelating group as a bridging group
GB202113646D0 (en) 2021-09-24 2021-11-10 Blue Earth Diagnostics Ltd Method of preparation of 18F labelled silyl-fluoride compounds
CN114671806B (zh) * 2022-04-08 2024-03-01 上海如絮生物科技有限公司 一种亲水性吡啶衍生物、中间体、其制备方法及应用
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds
WO2024023332A1 (en) 2022-07-29 2024-02-01 Technische Universität München Silicon-based fluoride acceptor groups for radiopharmaceuticals
WO2024054226A1 (en) * 2022-09-06 2024-03-14 Hoang Ba Xuan Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment
EP4631959A3 (en) * 2022-09-20 2025-12-17 Technische Universität München, in Vertretung des Freistaats Bayern Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白(fap)抑制劑、fap結合物及其診斷與治療用途
CN120417945A (zh) * 2022-11-14 2025-08-01 阿克提斯肿瘤学公司 肾脏中小蛋白滞留的减少
WO2025072791A2 (en) 2023-09-29 2025-04-03 Aktis Oncology, Inc. Miniproteins, conjugates & uses thereof
GB202316239D0 (en) 2023-10-24 2023-12-06 Blue Earth Diagnostics Ltd Therapeutic combination

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001346A1 (en) * 1993-06-30 1995-01-12 Akzo Nobel N.V. Chelating compounds
JP2005519861A (ja) * 2001-07-27 2005-07-07 ターゲサム・インコーポレーテッド 治療剤及び撮像剤としての脂質構築物
CN102626522B (zh) * 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
US10799605B2 (en) * 2014-06-10 2020-10-13 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
WO2016062370A1 (en) 2014-10-20 2016-04-28 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US20160287730A1 (en) * 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
JP7266365B2 (ja) * 2015-05-26 2023-04-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 分子および生体分子の18f標識化に有用な新規な複素芳香環フッ化ケイ素アクセプタおよびその調製方法
PL3658194T3 (pl) 2017-07-28 2025-09-15 Technische Universität München Radioznacznik i środki radioterapeutyczne o podwójnym trybie działania
CN116617421A (zh) * 2017-12-11 2023-08-22 慕尼黑工业大学 用于诊断和/或治疗的药物组合物
FI3917626T3 (fi) 2019-01-30 2023-08-17 Univ Muenchen Tech Psma:ta sitova kaksimuotoinen radiomerkkiaine ja terapeuttinen aine
KR20210153036A (ko) 2019-01-30 2021-12-16 테크니쉐 우니베르지테트 뮌헨 암 진단 영상화제들

Also Published As

Publication number Publication date
AU2024200440A1 (en) 2024-02-08
ZA202000467B (en) 2022-06-29
MX2020000352A (es) 2020-08-17
MX2023007914A (es) 2023-07-13
US11413360B2 (en) 2022-08-16
US20250121102A1 (en) 2025-04-17
SG11202000725WA (en) 2020-02-27
BR112020001785A2 (pt) 2020-09-29
JP2020528461A (ja) 2020-09-24
EA202090370A1 (ru) 2020-05-25
WO2019020831A1 (en) 2019-01-31
US12390540B2 (en) 2025-08-19
JP2022101601A (ja) 2022-07-06
KR102752620B1 (ko) 2025-01-10
EP4424378A3 (en) 2024-12-11
ES3011272T3 (en) 2025-04-07
AU2018308699B2 (en) 2023-11-30
HUE070098T2 (hu) 2025-05-28
EP4000640A1 (en) 2022-05-25
US12453787B2 (en) 2025-10-28
US20200197545A1 (en) 2020-06-25
JP7059372B2 (ja) 2022-04-25
IL272291A (en) 2020-03-31
EP3658194B1 (en) 2024-11-27
CN111132700A (zh) 2020-05-08
IL318092A (en) 2025-02-01
DK3658194T3 (da) 2025-02-17
EP3658194A1 (en) 2020-06-03
CA3071315A1 (en) 2019-01-31
KR20240027896A (ko) 2024-03-04
KR20200064057A (ko) 2020-06-05
AU2024200440B2 (en) 2025-04-24
PL3658194T3 (pl) 2025-09-15
AU2018308699A1 (en) 2020-01-23
IL272291B1 (en) 2025-02-01
CN111132700B (zh) 2022-12-13
PT3658194T (pt) 2025-02-13
US20220370649A1 (en) 2022-11-24
IL272291B2 (en) 2025-06-01
EP4424378A2 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
FI3658194T3 (fi) Dual mode -radiomerkkiaine ja -terapia
FI3796912T3 (fi) Antiproliferatiivisia yhdisteitä ja bcma:n ja cd3:n vastainen bispesifinen vasta-aine yhdistelmäkäyttöön
HRP20231501T1 (hr) Derivati benzizoksazolsulfonamida
IL313103B2 (en) Psma ligands for imaging and endoradiotherapy
HRP20230909T1 (hr) Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
JP2019502650A5 (ja) 抗ErbB2抗体−薬物コンジュゲート及びその組成物、そのための調製方法、並びにその使用
RU2018105846A (ru) Комбинация антагониста pd-1 с ингибитором egfr
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
MA56021A (fr) Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
SI2079486T1 (en) Effective synthesis of chelators for nuclear imaging and radiotherapy: composition and use
JP2016187356A5 (enExample)
HRP20201656T1 (hr) Neutralizacija inhibitornih putova u limfocitima
HRP20192254T1 (hr) Konjugat antitijela i lijeka i njegova upotreba u liječenju karcinoma
HRP20240215T1 (hr) Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate
JP2018530554A5 (enExample)
RU2009114161A (ru) Антитела и фрагменты антител человека против рецептора фолата альфа для радиоиммунотерапии карциномы яичника
EA201890473A1 (ru) Гетероарильные производные в качестве ингибиторов parp
HRP20191620T1 (hr) Grpr-antagonisti za otkrivanje, dijagnostiku i liječenje grpr-pozitivnog raka
HUP0201314A2 (hu) Aril-szubsztituált pirazolok, imidazolok, oxazolok, tiazolok és pirrolok, valamint ezek alkalmazása és az ezeket tartalmazó gyógyászati készítmények
MX2021013055A (es) Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos.
AU2016359514A1 (en) Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and application thereof
EA201892745A1 (ru) Фосфорамидатные производные нуклеозида в качестве противораковых агентов
JP2017533930A5 (enExample)
HRP20250655T1 (hr) Nova metoda za sintezu amanitina
EP3941525A4 (en) BENZODIAZEPIN DERIVATIVES AS RSV INHIBITORS